New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk
May 14, 2014 – New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk
New clinical guidelines recommend that health care providers consider pre-exposure prophylaxis (PrEP) for patients at substantial risk for HIV. PrEP is the use of anti-HIV drugs by people who do not have HIV to reduce the risk of infection.
For your stories about the new guidelines, please find below a press release – which provides key facts about PrEP and also outlines the specific indications for which PrEP is recommended – as well as other useful background resources on HIV.
- Press Release: New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk
- Guidelines: Morbidity and Mortality Weekly Report
- The 2014 PrEP guidelines are no longer maintained, but the 2017 PrEP guidelinesCdc-pdf are available
- Providers’ Supplement: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2014: Clinical
- The 2014 PrEP Providers’ Supplement is no longer maintained, but the 2017 PrEP Providers’ SupplementCdc-pdf is available
- Background Materials
You may download/link the following options of broadcast quality video and audio featuring NCHHSTP Director Jonathan Mermin, MD, MPH, talking about the new clinical guidelines that recommend health care providers consider pre-exposure prophylaxis (PrEP) for patients at substantial risk for HIV. Please note that these resources are for media use/reprint. If you are a member of the general public and seek additional information about HIV, please visit www.cdc.gov/hiv. If you have additional questions, please call 1(800) CDC INFO or email CDC-INFO.
Why is it Important?
- Video – Mp4Cdc-media
- Video – WmvCdc-media
- Sound – Mp3Cdc-media
- Caption File (srt)
- Caption File (xml)